Stockscreener 앱 받기
78.11
3.86%
2.90
시장 영업 전:
79.00
0.89
+1.14%
Cytokinetics Inc 주식(CYTK)의 최신 뉴스
Cytokinetics (CYTK) CEO Robert Blum sells 7,500 shares in open market trade - Stock Titan
Cytokinetics, Inc. (CYTK) Stock Analysis: Tapping into a Potential 49% Upside in the Biotech Sector - DirectorsTalk Interviews
Cytokinetics Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
Cytokinetics (CYTK) Launches MYQORZO in Germany for Obstructive HCM Treatment - Yahoo Finance
Cytokinetics, Incorporated Stock 12‑Month Price Target Raised to $106.58, Implies 52% Upside - TradingView
Monashee Investment Management LLC Sells 25,000 Shares of Cytokinetics, Incorporated $CYTK - MarketBeat
Cytokinetics, Incorporated $CYTK Shares Acquired by GW&K Investment Management LLC - MarketBeat
Insider Sell Alert: Fady Malik Sells 3,500 Shares of Cytokinetics Inc (CYTK) - GuruFocus
Cytokinetics EVP Malik sells $237,930 in shares By Investing.com - Investing.com Australia
Cytokinetics EVP Malik sells $237,930 in shares - Investing.com India
Cytokinetics (CYTK) EVP exercises options and sells 3,500 shares - Stock Titan
Nonprofits can seek up to $20K from Cytokinetics for health equity - Stock Titan
First MYQORZO Launch In Germany Might Change The Case For Investing In Cytokinetics (CYTK) - Yahoo Finance
807,070 Shares in Cytokinetics, Incorporated $CYTK Acquired by Norges Bank - MarketBeat
Cytokinetics, Inc. (CYTK) Stock Analysis: A Promising Biotech Player with Potential 46.47% Upside - DirectorsTalk Interviews
Cytokinetics Announces Call for Proposals for Annual Corporate Giving Program - Yahoo Finance
Cytokinetics, Incorporated $CYTK Stake Trimmed by TD Asset Management Inc - MarketBeat
Total liabilities & shareholders' equities of Cytokinetics, Incorporated – XETR:KK3A - TradingView
CYTK Q1 2026 Earnings: Narrower-Than-Expected Loss as Pipeline Progress ContinuesEarnings Power Value - newsline.com
Long term debt to total assets ratio of Cytokinetics, Incorporated – XETR:KK3A - TradingView
ETFs Investing in Cytokinetics, Incorporated Stocks - TradingView
Cytokinetics, Incorporated Trade Ideas — XETR:KK3A - TradingView
Cytokinetics prices $700 million stock offering at $71 per share - Investing.com
Truist raises Cytokinetics stock price target on positive trial data - Investing.com
J.P. Morgan Maintains Cytokinetics(CYTK.US) With Buy Rating, Maintains Target Price $97 - Moomoo
Cytokinetics says MYKORZO launch tops expectations as HCM data draws praise - MSN
Cytokinetics prices public offering of 9.8 mln shares at $71/share - marketscreener.com
Cytokinetics Inc (CYTK) News, Articles, Events & Latest Updates - Stocktwits
Why Is Cytokinetics (CYTK) Down 5.5% Since Last Earnings Report? - Yahoo Finance
BNP Paribas Financial Markets Purchases 332,397 Shares of Cytokinetics, Incorporated $CYTK - MarketBeat
Cytokinetics earnings on deck as trial results loom large By Investing.com - Investing.com Australia
Cytokinetics director Parshall sells $370,400 of CYTK stock By Investing.com - Investing.com South Africa
Insider Sell Alert: Kaye Edward M. MD Sells Shares of Cytokineti - GuruFocus
Cytokinetics EVP Andrew Callos sells $1.11m in stock By Investing.com - Investing.com Australia
Insider Sell Alert: B Parshall Sells 5,000 Shares of Cytokinetics Inc (CYTK) - GuruFocus
Cytokinetics director Edward Kaye sells $223,171 in shares By Investing.com - Investing.com Australia
Cytokinetics EVP Andrew Callos sells $1.11m in stock - Investing.com
Cytokinetics director Edward Kaye sells $223,171 in shares - Investing.com
Cytokinetics director Parshall sells $370,400 of CYTK stock - Investing.com
Cytokinetics (CYTK) director Kaye sells 2,933 shares at $76.09 - Stock Titan
CYTOKINETICS (CYTK) CCO exercises options and sells 15,000 shares at $74.08 - Stock Titan
Director Parshall trims Cytokinetics (CYTK) stake with 5,000-share sale - Stock Titan
[144] CYTOKINETICS INC SEC Filing - Stock Titan
Cytokinetics (CYTK) Launches Myqorzo in Germany for Heart Condition Treatment - GuruFocus
Cytokinetics announces launch of Myqorzo (aficamten) in Germany for symptomatic obstructive hypertrophic cardiomyopathy - marketscreener.com
Cytokinetics launches heart drug Myqorzo in Germany By Investing.com - Investing.com Australia
Cytokinetics launches heart drug Myqorzo in Germany - Investing.com
Cytokinetics Announces European Launch of MYQORZO® (aficamten) for Obstructive Hypertrophic Cardiomyopathy in Germany Following U.S. Approval - Quiver Quantitative
Cytokinetics launches Myqorzo® (aficamten) in European Union, with first commercial availability in Germany - marketscreener.com
Cytokinetics Launches MYQORZO® (aficamten) in European Union, with First Commercial Availability in Germany - The Manila Times
New heart drug MYQORZO reaches German patients with obstructive HCM - Stock Titan
2.60%
0.94%
자본화:
|
볼륨(24시간):